Loggi Elisabetta, Conti Fabio, Cucchetti Alessandro, Ercolani Giorgio, Pinna Antonio Daniele, Andreone Pietro
Elisabetta Loggi, Fabio Conti, Alessandro Cucchetti, Giorgio Ercolani, Antonio Daniele Pinna, Pietro Andreone, Dipartimento di Scienze Mediche e Chirurgiche, Università degli Studi di Bologna, 40138 Bologna, Italy.
World J Gastroenterol. 2016 Sep 21;22(35):8010-6. doi: 10.3748/wjg.v22.i35.8010.
The scarcity of available organs and the gap between supply and demand continue to be the main limitations of liver transplantation. To relieve the organ shortage, current transplant strategies have implemented extended criteria, which include the use of liver from patients with signs of past or present hepatitis B virus (HBV) infection. While the use of liver grafts from donors with evidence of past HBV infection is quite limited, some data have been collected regarding the feasibility of transplanting a liver graft from a hepatitis B surface antigen (HBsAg) positive donor. The aim of the present work was to review the literature regarding liver transplants from HBsAg-positive donors. A total of 17 studies were identified by a search in Medline. To date, HBsAg positive grafts have preferentially been allocated to HBsAg positive recipients. The large majority of these patients continue to be HBsAg positive despite the use of immunoglobulin, and infection prevention can only be guaranteed by using antiviral prophylaxis. Although serological persistence is evident, no significant HBV-related disease has been observed, except in patients coinfected with delta virus. Consistently less data are available for HBsAg negative recipients, although they are mostly promising. HBsAg-positive grafts could be an additional organ source for liver transplantation, provided that the risk of reinfection/reactivation is properly prevented.
可用器官的稀缺以及供需差距仍然是肝移植的主要局限性。为缓解器官短缺问题,当前的移植策略已采用扩展标准,其中包括使用曾感染或现感染乙型肝炎病毒(HBV)患者的肝脏。虽然使用有既往HBV感染证据的供体肝脏的情况相当有限,但已收集了一些关于移植来自乙型肝炎表面抗原(HBsAg)阳性供体肝脏的可行性的数据。本研究的目的是回顾关于HBsAg阳性供体肝移植的文献。通过检索Medline共识别出17项研究。迄今为止,HBsAg阳性移植物优先分配给HBsAg阳性受者。尽管使用了免疫球蛋白,但这些患者中的绝大多数仍然HBsAg阳性,并且只有通过使用抗病毒预防措施才能保证预防感染。虽然血清学持续存在很明显,但除了丁型病毒合并感染的患者外,未观察到明显的HBV相关疾病。对于HBsAg阴性受者,尽管大多前景良好,但可用数据一直较少。如果能适当预防再感染/再激活风险,HBsAg阳性移植物可能成为肝移植的额外器官来源。